Advances of bifunctional anti-PD-L1/TGF-β fusion protein M7824
10.3760/cma.j.issn.1673-422X.2019.05.006
- VernacularTitle:PD-L1/TGF-β双功能抑制剂融合蛋白M7824研究进展
- Author:
Mengxue HU
1
;
Bin XU
;
Jinming YU
;
Qibin SONG
Author Information
1. 武汉大学人民医院肿瘤中心 430060
- Keywords:
Recombinant fusion proteins;
Transforming growth factor β;
PD-L1;
M7824
- From:
Journal of International Oncology
2019;46(5):281-284
- CountryChina
- Language:Chinese
-
Abstract:
With the development of programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors,the second generation of combined immunosuppressive agents emerge as the times require.As a bifunctional anti-PD-L1/transforming growth factor-β (TGF-β) fusion protein,M7824 can antagonize PD-L1 pathway and trap TGF-β at the same time,which can effectively enhance the immune response and reduce the occurrence of immune escape and drug resistance.The drug has achieved remarkable results in many preclinical studies,however,the indications,safety and efficacy still need to be confirmed by large-scale clinical research data.
